Skip to content
Screener

Xencor XNCR Other Income (Expense)

Other Income (Expense) at other companies

Amgen logo
AmgenAMGN
-$73M+81.5%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$234.3M-46.7%
Janux Therapeutics logo
Janux TherapeuticsJANX
$9.72M-13.7%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$3.81M-71.2%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$18.21M-55.0%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$717.17K+377%

Other financials

Income statement

See full
Revenue$51.2M+17.5%
Operating income-$37.1M-11.7%
Net income-$21.7M+29.5%
EPS (diluted)-$0.29+29.3%

Balance sheet

See full
Cash & equivalents$44.7M+0.5%
Total debt$170.1M-20.1%
Total equity$503.2M-18.9%
Total assets$725.0M-17.6%

Cash flow

See full
Operating cash flow-$55.7M-53.0%
CapEx$538.0K+40.5%
Free cash flow-$56.2M-52.9%

Valuation

See full
Market cap$1.6B+221%
Enterprise value$1.73B+159%
P/S15.3×+11.9×

Profitability

See full
Operating margin-205.8%-2,501pp
Net margin-155.6%+78.8pp
FCF margin-198.4%-1,485pp

Returns & leverage

See full
Return on equity-29.1%+0.2pp
Debt / equity0.3×0.0×
Current ratio6.4×+1.1×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The source filing: Xencor’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:02 PM EDT
Fiscal quarter
Q4 FY2028
Calendar quarter
Q4 2028
Accession
0001326732-26-000056
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Gains (losses) on equity securities, net18,0644,967(33,865)5,908
Asset impairment charges(797)(1,858)(797)(6,723)
Other, net434(17)830(48)
Total other income (expense)15,1492,097(35,625)(2,985)
Loss before income tax expense (benefit) and noncontrolling interest(21,919)(31,075)(150,555)(79,340)
Income tax (benefit) expense(190)(250)90117
Net loss including noncontrolling interest(21,729)(30,825)(150,645)(79,457)
Net loss attributable to noncontrolling interest(214)

Item 1. Financial Statements

FAQ

What is Xencor's other income (expense)?
Xencor (XNCR) reported other income (expense) of $15.15M in Q2 2026.
How has Xencor's other income (expense) changed year-over-year?
Xencor's other income (expense) increased by 622.4% year-over-year, from $2.1M to $15.15M.
What is the long-term trend for Xencor's other income (expense)?
Over 3 years (2022 to 2025), Xencor's other income (expense) has grown at a 46.5% compound annual growth rate (CAGR), from $27.97M to $87.87M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about Xencor's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude